|
1
|
Chiu BC and Weisenburger DD: An update of
the epidemiology of non-Hodgkin's lymphoma. Clin Lymphoma.
4:161–168. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Advani A, Coiffier B, Czuczman MS,
Dreyling M, Foran J, Gine E, Gisselbrecht C, Ketterer N, Nasta S,
Rohatiner A, et al: Safety, pharmacokinetics, and preliminary
clinical activity of inotuzumab ozogamicin, a novel immunoconjugate
for the treatment of B-cell non-Hodgkin's lymphoma: Results of a
phase I study. J Clin Oncol. 28:2085–2093. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Maxwell SA and Mousavi-Fard S:
Non-Hodgkin's B-cell lymphoma: Advances in molecular strategies
targeting drug resistance. Exp Biol Med. 238:971–990. 2013.
View Article : Google Scholar
|
|
4
|
Huang X, Meng B, Iqbal J, Ding BB, Perry
AM, Cao W, Smith LM, Bi C, Jiang C, Greiner TC, et al: Activation
of the STAT3 signaling pathway is associated with poor survival in
diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol.
31:4520–4528. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bohers E, Mareschal S, Bouzelfen A,
Marchand V, Ruminy P, Maingonnat C, Ménard AL, Etancelin P,
Bertrand P, Dubois S, et al: Targetable activating mutations are
very frequent in GCB and ABC diffuse large B-cell lymphoma. Genes
Chromosomes Cancer. 53:144–153. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Duong HQ, Hwang JS, Kim HJ, Kang HJ, Seong
YS and Bae I: Aldehyde dehydrogenase 1A1 confers intrinsic and
acquired resistance to gemcitabine in human pancreatic
adenocarcinoma MIA PaCa-2 cells. Int J Oncol. 41:855–861. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schäfer A, Teufel J, Ringel F, Bettstetter
M, Hoepner I, Rasper M, Gempt J, Koeritzer J, Schmidt-Graf F, Meyer
B, et al: Aldehyde dehydrogenase 1A1-a new mediator of resistance
to temozolomide in glioblastoma. Neuro Oncol. 14:1452–1464. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shien K, Toyooka S, Yamamoto H, Soh J,
Jida M, Thu KL, Hashida S, Maki Y, Ichihara E, Asano H, et al:
Acquired resistance to EGFR inhibitors is associated with a
manifestation of stem cell-like properties in cancer cells. Cancer
Res. 73:3051–3061. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Alamgeer M, Ganju V, Szczepny A, Russell
PA, Prodanovic Z, Kumar B, Wainer Z, Brown T, Schneider-Kolsky M,
Conron M, et al: The prognostic significance of aldehyde
dehydrogenase 1A1 (ALDH1A1) and CD133 expression in early stage
non-small cell lung cancer. Thorax. 68:1095–1104. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
de Beça FF, Caetano P, Gerhard R,
Alvarenga CA, Gomes M, Paredes J and Schmitt F: Cancer stem cells
markers CD44, CD24 and ALDH1 in breast cancer special histological
types. J Clin Pathol. 66:187–191. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shen M, Bunaciu RP, Congleton J, Jensen
HA, Sayam LG, Varner JD and Yen A: Interferon regulatory factor-1
binds c-Cbl, enhances mitogen activated protein kinase signalingand
promotes retinoic acid-induced differentiation of HL-60 human
myelo-monoblastic leukemia cells. Leuk Lymphoma. 52:2372–2379.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ikeda J, Mamat S, Tian T, Wang Y, Luo W,
Rahadiani N, Aozasa K and Morii E: Reactive oxygen species and
aldehyde dehydrogenase activity in Hodgkin lymphoma cells. Lab
Invest. 92:606–614. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Neradugomma NK, Subramaniam D, Tawfik OW,
Goffin V, Kumar TR, Jensen RA and Anant S: Prolactin signaling
enhances colon cancer stemness by modulating Notch signaling in a
Jak2-STAT3/ERK manner. Carcinogenesis. 35:795–806. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu L, Salnikov AV, Bauer N,
Aleksandrowicz E, Labsch S, Nwaeburu C, Mattern J, Gladkich J,
Schemmer P, Werner J and Herr I: Triptolide reverses
hypoxia-induced epithelial-mesenchymal transition and stem-like
features inpancreatic cancer by NF-κB downregulation. Int J Cancer.
134:2489–2503. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Song YH, Zhong MZ, Gan PP, Yi PY, Tang YH,
Liu YP, Jiang JQ and Li L: ALDH1A1 mediates resistance of diffuse
large B cell lymphoma to the CHOP regimen. Tumour Biol.
35:11809–11817. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fujita S, Morii E, Rahadiani N, Wada N,
Hori Y, Ikeda JI and Aozasa K: Significance of aldehyde
dehydrogenase 1 expression in stromal cells of diffuse large B-cell
lymphoma. Exp Ther Med. 2:591–594. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jiang J, Liu Y, Tang Y, Li L, Zeng R, Zeng
S and Zhong M: ALDH1A1 induces resistance to CHOP in diffuse large
B-cell lymphoma through activation of the JAK2/STAT3 pathway. Onco
Targets Ther. 9:5349–5360. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wilson WH, Teruya-Feldstein J, Fest T,
Harris C, Steinberg SM, Jaffe ES and Raffeld M: Relationship of
p53, bcl-2, and tumor proliferation to clinical drug resistance in
non-Hodgkin's lymphomas. Blood. 89:601–609. 1997.PubMed/NCBI
|
|
19
|
Maxwell SA, Li Z, Jaye D, Ballard S,
Ferrell J and Fu H: 14-3-3zeta mediates resistance of diffuse large
B cell lymphoma to an anthracycline-based chemotherapeutic regimen.
J Biol Chem. 284:22379–22389. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou Y, Wang Y, Ju X, Lan J, Zou H, Li S,
Qi Y, Jia W, Hu J, Liang W, et al: Clinicopathological significance
of ALDH1A1 in lung, colorectal, and breast cancers: A
meta-analysis. Biomark Med. 9:777–790. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jones RJ, Gocke CD, Kasamon YL, Miller CB,
Perkins B, Barber JP, Vala MS, Gerber JM, Gellert LL, Siedner M, et
al: Circulating clonotypic B cells in classic Hodgkin lymphoma.
Blood. 113:5920–5926. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ng SB, Ohshima K, Selvarajan V, Huang G,
Choo SN, Miyoshi H, Shimizu N, Reghunathan R, Chua HC, Yeoh AE, et
al: Epstein-Barr virus-associated T/natural killer-cell
lymphoproliferative disorder in children and young adults has
similar molecular signature to extranodal nasal natural
killer/T-cell lymphoma but shows distinctive stem cell-like
phenotype. Leuk Lymphoma. 56:2408–2415. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Brennan SK, Meade B, Wang Q, Merchant AA,
Kowalski J and Matsui W: Mantle cell lymphoma activation enhances
bortezomib sensitivity. Blood. 116:4185–4191. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jiang L, Yu K, Du J, Ni W, Han Y, Gao S,
Li H, Wu J, Zheng Y and Tan Y: Inhibition of p38 MAPK activity in
B-NHL Raji cells by treatment with engineered CD20-specific T
cells. Oncol Lett. 2:753–758. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pham LV, Tamayo AT, Yoshimura LC, Lo P,
Terry N, Reid PS and Ford RJ: A CD40 Signalosome anchored in lipid
rafts leads to constitutive activation of NF-kappaB andautonomous
cell growth in B cell lymphomas. Immunity. 16:37–50. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang H, Chen Z, Miranda RN, Medeiros LJ
and McCarty N: TG2 and NF-κB signaling coordinates the survival of
mantle cell lymphoma cells via IL6-mediated autophagy. Cancer Res.
76:6410–6423. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ezell SA, Mayo M, Bihani T, Tepsuporn S,
Wang S, Passino M, Grosskurth SE, Collins M, Parmentier J, Reimer C
and Byth KF: Synergistic induction of apoptosis by combination of
BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma.
Oncotarget. 5:4990–5001. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Koppaka V, Thompson DC, Chen Y, Ellermann
M, Nicolaou KC, Juvonen RO, Petersen D, Deitrich RA, Hurley TD and
Vasiliou V: Aldehyde dehydrogenase inhibitors: A comprehensive
review of the pharmacology, mechanism of action, substrate
specificity, and clinical application. Pharmacol Rev. 64:520–539.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lin J, Haffner MC, Zhang Y, Lee BH,
Brennen WN, Britton J, Kachhap SK, Shim JS, Liu JO, Nelson WG, et
al: Disulfiram is a DNA demethylating agent and inhibits prostate
cancer cell growth. Prostate. 71:333–343. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kim JY, Cho Y, Oh E, Lee N, An H, Sung D,
Cho TM and Seo JH: Disulfiram targets cancer stem-like properties
and the HER2/Akt signaling pathway in HER2-positive breast cancer.
Cancer Lett. 379:39–48. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu X, Wang L, Cui W, Yuan X, Lin L, Cao
Q, Wang N, Li Y, Guo W, Zhang X, et al: Targeting ALDH1A1 by
disulfiram/copper complex inhibits non-small cell lung cancer
recurrence driven by ALDH-positive cancer stem cells. Oncotarget.
7:58516–58530. 2016.PubMed/NCBI
|
|
32
|
Paranjpe A, Zhang R, Ali-Osman F, Bobustuc
GC and Srivenugopal KS: Disulfiram is a direct and potent inhibitor
of human O6-methylguanine-DNA methyltransferase (MGMT)
in brain tumor cells and mouse brain and markedly increases the
alkylating DNA damage. Carcinogenesis. 35:692–702. 2014. View Article : Google Scholar : PubMed/NCBI
|
